A phase 1/2 study of metronomic 5-fluorouracil (5-FU) plus nabpaclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with metastatic pancreatic cancer

被引：0
|
作者：
Vincent, Picozzi [1 ]
Vaibhav, Sahai [2 ]
Diane, Simeone [2 ]
Caio, Rocha Lima [3 ]
Allyson, Ocean [4 ]
Philip, Philip [5 ]
Wasif, Saif [6 ]
Aparna, Kalyan [7 ]
Michael, Ondovik [8 ]
Jack, Shiansong Li [8 ]
Chrystal, Louis [8 ]
机构：
[1] Virginia Mason, Seattle, WA USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Gibbs Canc Ctr, Res Inst, Spartanburg, SC USA
[4] Weill Cornell Med Coll, New York, NY USA
[5] Karmanos Canc Ctr, Detroit, MI USA
[6] Tufts Med Ctr, Boston, MA USA
[7] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[8] Celgene Corp, Summit, NJ USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-231
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Oxaliplatin (LOHP) and 5-fluorouracil (5-FU) synergism in advanced colorectal cancer patients (ACRC)
    Meyer, V
    Delva, R
    Gamelin, E
    Lamezec, B
    Maillart, P
    DanquechinDorval, E
    Lortholary, A
    BoisdronCelle, M
    Maigre, M
    Brienza, S
    Cvitkovic, E
    Larra, F
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 746 - 746
  • [32] A phase I study of ZD 1839 (Iressa) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) in advanced solid malignancies
    Fisher, GA
    Cho, CD
    Halsey, JZ
    Advani, RH
    Yuen, AR
    Lum, BL
    Sikic, BI
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S63 - S63
  • [33] Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU), and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer
    Kim, G. P.
    Haddock, M.
    Foster, N. R.
    Bollinger, J.
    Stella, P. J.
    Kugler, J. W.
    Alberts, S. R.
    Martenson, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study
    Emmanouilides, Christos
    Sfakiotaki, Georgia
    Androulakis, Nikolaos
    Kalbakis, Kostas
    Christophylakis, Charalambos
    Kalykaki, Antonia
    Vamvakas, Lambros
    Kotsakis, Athanasios
    Agelaki, Sofia
    Diamandidou, Eleni
    Touroutoglou, Nikolaos
    Chatzidakis, Adam
    Georgoulias, Vassilis
    Mavroudis, Dimitris
    Souglakos, John
    BMC CANCER, 2007, 7 (1)
  • [35] Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study
    Christos Emmanouilides
    Georgia Sfakiotaki
    Nikolaos Androulakis
    Kostas Kalbakis
    Charalambos Christophylakis
    Antonia Kalykaki
    Lambros Vamvakas
    Athanasios Kotsakis
    Sofia Agelaki
    Eleni Diamandidou
    Nikolaos Touroutoglou
    Adam Chatzidakis
    Vassilis Georgoulias
    Dimitris Mavroudis
    John Souglakos
    BMC Cancer, 7
  • [36] Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer
    Marantz, A
    Jovtis, S
    Almira, E
    Balbiani, L
    Castilla, JL
    Fein, L
    Lewi, D
    Pasccon, G
    Pinckevicius, R
    Uranga, G
    Abal, M
    Muiño, M
    Reale, M
    Agusto, S
    Lastiri, F
    SEMINARS IN ONCOLOGY, 2001, 28 (03) : 44 - 49
  • [37] Phase I study of oxaliplatin in combination with 5-fluorouracil (5-FU), leucovorin (LV) and capecitabine (ORAL FOLFOX-6) in patients with advanced or metastatic solid tumors.
    Hegeman, RB
    Mulkerin, D
    Thomas, J
    Alberti, D
    Binger, K
    Marnocha, R
    Kolesar, J
    Wilding, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 149S - 149S
  • [38] First-line chemotherapy with low-dose leucovorin plus 5-fluorouracil (LV/5-FU) for elderly patients with metastatic colorectal cancer
    Yoshimatsu, Kazuhiko
    Yokomizo, Hajime
    Fujimoto, Takashi
    Umehara, Arihiro
    Otani, Taisuke
    Matsumoto, Atsuo
    Osawa, Gakuji
    Shiozawa, Shunichi
    Katsube, Takao
    Naritaka, Yoshihiko
    Ogawa, Kenji
    ANTICANCER RESEARCH, 2007, 27 (3B) : 1641 - 1644
  • [39] Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer
    McWilliams, Robert R.
    Goetz, Matthew P.
    Morlan, Bruce W.
    Salim, Muhammad
    Rowland, Kendrith M.
    Krook, James E.
    Ames, Matthew M.
    Erlichman, Charles
    CLINICAL COLORECTAL CANCER, 2007, 6 (07) : 516 - 521
  • [40] COMPARATIVE PHASE 2 STUDY OF INFUSIONAL 5, 10-METHYLENETETRAHYDROFOLATE WITH 5-FLUOROURACIL (FU) VERSUS LEUCOVORIN (LV) WITH FU IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Cassidy, J.
    Jelic, S.
    Pluzanska, A.
    Ciuleanu, T.
    Babu, K. G.
    Stewart, J.
    Schupp, J. P. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 130 - 130
12345